Reset Map4 Results
Yalelaan 62 Utrecht, 3584 CM NetherlandsSolvias NL is a genomics-focused biotechnology company that developed the patented Targeted Locus Amplification (TLA) technology, a widely published Next Generation Sequencing (NGS)-based enrichment strategy. Thanks to its unique resolution and unmatched capabilities, TLA offers unique advantages in the quality control of advanced genetic engineering. Our TLA-based genetic solutions can be applied to determine: • All sequence changes resulting from targeted genome editing. • All vector integration sites. • Structural changes in the host genome surrounding vector integration sites. • Single nucleotide variants in a vector sequence. • Structural changes in a vector sequence. • Co-integration of backbone or contaminating E.coli sequences Cergentis has established itself as the go-to partner for the characterization of genetically engineered cell lines, cell and gene therapy products and animal models for the global biopharmaceutical industry and leading research institutes. We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provide services for the support in R&D in these fields. Our expertise lies in the analysis of (complex) genetic engineering projects in various organisms and sample types, including CHO, human cell lines (T cells, HEK293, HeLa, etc.) and transgenic animals (mice, rats, goats, pigs, etc.). TLA data is widely used in the selection and characterization of genetically engineered cell lines and animals and has been widely used in support of >70 peer-reviewed publications. TLA obsoletes the use of southern blot and FISH, yielding NGS-based data at a fraction of the turnaround time and costs. Moreover, Cergentis studies are performed and reported to be acceptable for regulatory filings in accordance with FDA and EMA requirements (CTD module 3.2.S.2.3.) and have been used in both early (IND) and late stage (BLA) dossiers. It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.
62 Yalelaan Utrecht, UT, 3584 NetherlandsSolvias NL is a genomics-focused biotechnology company that developed the patented Targeted Locus Amplification (TLA) technology, a widely published Next Generation Sequencing (NGS)-based enrichment strategy. Thanks to its unique resolution and unmatched capabilities, TLA offers unique advantages in the quality control of advanced genetic engineering. Our TLA-based genetic solutions can be applied to determine: • All sequence changes resulting from targeted genome editing. • All vector integration sites. • Structural changes in the host genome surrounding vector integration sites. • Single nucleotide variants in a vector sequence. • Structural changes in a vector sequence. • Co-integration of backbone or contaminating E.coli sequences Cergentis has established itself as the go-to partner for the characterization of genetically engineered cell lines, cell and gene therapy products and animal models for the global biopharmaceutical industry and leading research institutes. We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provide services for the support in R&D in these fields. Our expertise lies in the analysis of (complex) genetic engineering projects in various organisms and sample types, including CHO, human cell lines (T cells, HEK293, HeLa, etc.) and transgenic animals (mice, rats, goats, pigs, etc.). TLA data is widely used in the selection and characterization of genetically engineered cell lines and animals and has been widely used in support of >70 peer-reviewed publications. TLA obsoletes the use of southern blot and FISH, yielding NGS-based data at a fraction of the turnaround time and costs. Moreover, Cergentis studies are performed and reported to be acceptable for regulatory filings in accordance with FDA and EMA requirements (CTD module 3.2.S.2.3.) and have been used in both early (IND) and late stage (BLA) dossiers. It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.
Yalelaan 62 Utrecht, UTRECHT, 3584CM NetherlandsSolvias NL is a genomics-focused biotechnology company that developed the patented Targeted Locus Amplification (TLA) technology, a widely published Next Generation Sequencing (NGS)-based enrichment strategy. Thanks to its unique resolution and unmatched capabilities, TLA offers unique advantages in the quality control of advanced genetic engineering. Our TLA-based genetic solutions can be applied to determine: • All sequence changes resulting from targeted genome editing. • All vector integration sites. • Structural changes in the host genome surrounding vector integration sites. • Single nucleotide variants in a vector sequence. • Structural changes in a vector sequence. • Co-integration of backbone or contaminating E.coli sequences Cergentis has established itself as the go-to partner for the characterization of genetically engineered cell lines, cell and gene therapy products and animal models for the global biopharmaceutical industry and leading research institutes. We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provide services for the support in R&D in these fields. Our expertise lies in the analysis of (complex) genetic engineering projects in various organisms and sample types, including CHO, human cell lines (T cells, HEK293, HeLa, etc.) and transgenic animals (mice, rats, goats, pigs, etc.). TLA data is widely used in the selection and characterization of genetically engineered cell lines and animals and has been widely used in support of >70 peer-reviewed publications. TLA obsoletes the use of southern blot and FISH, yielding NGS-based data at a fraction of the turnaround time and costs. Moreover, Cergentis studies are performed and reported to be acceptable for regulatory filings in accordance with FDA and EMA requirements (CTD module 3.2.S.2.3.) and have been used in both early (IND) and late stage (BLA) dossiers. It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.
Yalelaan 62 UTRECHT, 3584CM NetherlandsSolvias NL is a genomics-focused biotechnology company that developed the patented Targeted Locus Amplification (TLA) technology, a widely published Next Generation Sequencing (NGS)-based enrichment strategy. Thanks to its unique resolution and unmatched capabilities, TLA offers unique advantages in the quality control of advanced genetic engineering. Our TLA-based genetic solutions can be applied to determine: • All sequence changes resulting from targeted genome editing. • All vector integration sites. • Structural changes in the host genome surrounding vector integration sites. • Single nucleotide variants in a vector sequence. • Structural changes in a vector sequence. • Co-integration of backbone or contaminating E.coli sequences Cergentis has established itself as the go-to partner for the characterization of genetically engineered cell lines, cell and gene therapy products and animal models for the global biopharmaceutical industry and leading research institutes. We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provide services for the support in R&D in these fields. Our expertise lies in the analysis of (complex) genetic engineering projects in various organisms and sample types, including CHO, human cell lines (T cells, HEK293, HeLa, etc.) and transgenic animals (mice, rats, goats, pigs, etc.). TLA data is widely used in the selection and characterization of genetically engineered cell lines and animals and has been widely used in support of >70 peer-reviewed publications. TLA obsoletes the use of southern blot and FISH, yielding NGS-based data at a fraction of the turnaround time and costs. Moreover, Cergentis studies are performed and reported to be acceptable for regulatory filings in accordance with FDA and EMA requirements (CTD module 3.2.S.2.3.) and have been used in both early (IND) and late stage (BLA) dossiers. It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.